Prospects for Alkem and Lupin's cetuximab biosimilars in India
Indian drugmakers Alkem Laboratories (BSE: 539523) and Lupin Limited (BSE: 500257) have recently launched the world’s first cetuximab biosimilar in India for the treatment of head and neck cancer (HNC). Cetuximab is the active ingredient of German pharma firm Merck KGaA’s (MRK: DE) Erbitux.
With this, Alkem and Lupin are in a unique position to improve their brand equity within the oncology therapy area in India, says data and analytics company GlobalData.
Alkem’s subsidiary Enzene Biosciences received cetuximab biosimilar approval in India in January 2023. Lupin partnered with Enzene Biosciences in May to launch cetuximab biosimilar in India. Alkem and Lupin already have a portfolio of biosimilars within the oncology therapy area, including bevacizumab biosimilars, trastuzumab biosimilars, and rituximab biosimilars in India. However, the biosimilars market segment in the country is highly competitive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze